Report error Found 380 of ic50 data for polymerid = 8174
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0250nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0320nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0400nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0400nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0400nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0500nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0500nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0540nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0630nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0630nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0630nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.0850nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.102nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.102nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.102nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.110nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.110nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.110nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.112nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.120nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.120nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.120nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.120nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.126nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.135nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.138nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.145nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.150nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.158nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand Info
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.174nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.174nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.204nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.210nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.214nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
BenevolentAI Cambridge Limited
US Patent
BenevolentAI Cambridge Limited
US Patent
Affinity DataIC50: 0.220nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
